Forte Biosciences appoints Dr. Hubert Chen as President and CSO

Forte Biosciences, Inc.

Dr. Chen appointed President and Chief Scientific Officer effective June 7, 2022; Paul Wagner remains CEO.
Annual base salary of $450,000, target annual bonus of 40% of base salary, and option for 250,000 shares.
Dr. Chen previously served as CMO of Metacrine and CSO/CMO of Pfenex, leading PF708 NDA and MAA approvals.
Options vest 25% after one year, remaining monthly over 36 months; grant under 2020 Inducement Equity Incentive Plan.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Paul A. Wagner

President

FBRX · Forte Biosciences, Inc.

Effective: 2022-06-07
Successor: Hubert C. Chen
Filed: June 7, 2022, 7:59 PM ET

the title of President of the Company transitioned from Paul A. Wagner, Ph.D. to Dr. Chen, provided that Dr. Wagner will continue to serve as the Company’s Chief Executive Officer and a member of the Board.

Appointed

Hubert C. Chen

President and Chief Scientific Officer

FBRX · Forte Biosciences, Inc.

Effective: 2022-06-07
Filed: June 7, 2022, 7:59 PM ET

On June 5, 2022, the Board of Directors (“Board”) of Forte Biosciences, Inc. (the “Company”) appointed Hubert C. Chen, M.D. to serve as President and Chief Scientific Officer of the Company, effective June 7, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Paul A. Wagner changed role as President at Forte Biosciences, Inc..

Action: transitioned
Role: President

Exact text from the filing

the title of President of the Company transitioned from Paul A. Wagner, Ph.D. to Dr. Chen, provided that Dr. Wagner will continue to serve as the Company’s Chief Executive Officer and a member of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Hubert C. Chen was appointed as President and Chief Scientific Officer at Forte Biosciences, Inc..

Action: appointed
Role: President and Chief Scientific Officer

Exact text from the filing

On June 5, 2022, the Board of Directors (“Board”) of Forte Biosciences, Inc. (the “Company”) appointed Hubert C. Chen, M.D. to serve as President and Chief Scientific Officer of the Company, effective June 7, 2022.

View on SEC.gov

Forte Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-168911

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.